Peng et al.' research showed that metformin and gefitinib could jointly inhibit the growth of bladder cancer through the AMPK and EGFR pathways, providing a new solution for postoperative infusion chemotherapy for bladder cancer [14]. Here, EGFR is linked to urinary bladder cancer.